(INNS)
ZIFIBANCIMIG(INND)
ZIFIBANCIMIG(INNC)
IMMUNOGLOBULIN FAB G1-KAPPA, ANTI-[HOMO SAPIENS ANGPT2 (ANGIOPOIETIN 2, ANG2)] AND ANTI-[HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A, VEGF-A, VEGF), MONOCLONAL ANTIBODY, BISPECIFIC, BIPARATOPE MONOVALENT; VH-(CH1-HINGE) GAMMA1 HEAVY CHAIN (1-223) [VH (HOMO SAPIENS IGHV3-31*07 (74.0%) -(IGHD) -IGHJ4*01 (86.7%), CDR-IMGT [7.8.9] (26-32.50-57.96-104)) (1-115) -CH1-HINGE (HOMO SAPIENS IGHG1*01 (100%), G1M17 (CH1 K120 (212) (116-213), HINGE 1-10 (214-223)) (116-223)], (218-214')- DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [V-KAPPA (HOMO SAPIENS IGKV1- 5*01 (72.2%) -IGKJ4*01 (90.9%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')]; BISPECIFIC, BIPARATOPE MONOVALENT: ANTI-ANG2 PARATOPE (VH CDR1 AND CDR3, V-KAPPA CDR2) AND ANTI-VEGFA PARATOPE (V-KAPPA CDR1 AND CDR3, VH CDR2), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, NON-GLYCOSYLATED(WHO)
ZIFIBANCIMIGUM(INN)